NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
Kairos Pharma 2025 Milestones and ENV105 Clinical Progress FAQ
TL;DR
Kairos Pharma's ENV105 shows 86% clinical benefit in prostate cancer trials, potentially creating a competitive advantage in oncology therapeutics and investor opportunities.
ENV105 targets CD105 protein to reverse drug resistance, combining with apalutamide in Phase 2 trials with no dose-limiting toxicities and durable progression-free survival.
This cancer treatment advancement brings hope for improved patient outcomes and quality of life for those battling advanced metastatic prostate cancer worldwide.
Kairos Pharma's innovative antibody therapy targets cancer drug resistance mechanisms, showing promising results that could transform standard prostate cancer treatment approaches.
Found this article helpful?
Share it with your network and spread the knowledge!
The letter outlines 2025 accomplishments and the 2026 outlook, highlighting positive interim safety and efficacy results from the Phase 2 trial of ENV105 in combination with apalutamide for advanced metastatic prostate cancer.
The trial showed clinical benefit in 86% of treated patients with durable progression-free survival and no dose-limiting toxicities, suggesting ENV105 may extend the effectiveness of standard care while maintaining strong tolerability.
ENV105 is an antibody that targets CD105, a protein identified as a key driver of resistance to various cancer treatments. It aims to reverse drug resistance by targeting CD105 and restore the effectiveness of standard therapies across multiple cancer types.
ENV105 is currently in a Phase 2 clinical trial for castrate-resistant prostate cancer and a Phase 1 trial for lung cancer, both aimed at addressing significant unmet medical needs.
The findings were presented at the European Society for Medical Oncologists Meeting.
Kairos continues patient recruitment, with enrollment expected to reach 100 across leading U.S. cancer centers.
Elevation of CD105 in response to standard therapy results in resistance and disease relapse, so targeting it aims to reverse drug resistance and restore the effectiveness of standard therapies.
Kairos Pharma is based in Los Angeles, California and trades on the NYSE American under the symbol KAPA.
The latest news and updates relating to KAPA are available in the company's newsroom at https://ibn.fm/KAPA
The results suggest ENV105 may extend the effectiveness of standard care while maintaining strong tolerability, potentially offering improved treatment options for patients with advanced metastatic prostate cancer.
Curated from InvestorBrandNetwork (IBN)
